Alpha¹ by KaimenConfidential

Kaimen Rigor review

Reduced-energy diet in women with gestational diabetes: the dietary intervention in gestational diabetes DiGest randomized clinical trial.

Kusinski LC, Jones D, Atta N, Turner E, Smith S, Oude Griep LM, Rennie K, De Lucia Rolfe E, Sharp SJ, Farewell V, Murphy HR, Taylor R, Meek CL

DOI: 10.1038/s41591-024-03356-1
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/4c8d00b7-5c94-4e36-bd0a-aec53b0671d6 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsOverstated claim ×2−1★
StatisticsStatistic did not reproduce−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Printed percentage does not match its own count
highArithmeticrecomputedFull detail
90.1% does not match the reported count 388/425
“388 of 425 (90.1%)”
Find in source
02Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is that a reduced-energy diet reduces the requirement for long-acting insulin in gestational diabetes. This is a surrogate outcome (medication requirement) rather than a hard clinical outcome. The paper does not demonstrate target engagement at the tested dose (e.g., no PK/PD or dose-exposure data linking the 1200 kcal diet to insulin requirement reduction) and does not cite validated evidence linking reduced insulin requirement to improved long-term clinical outcomes in gestational diabetes. The primary outcomes (maternal weight change and offspring birth weight) showed no difference, so the efficacy claim rests on this secondary surrogate.
“Provision of a reduced-energy diet reduced requirements for long-acting insulin therapy (39.2% control, 27.5% intervention; odds ratio (OR) 0.36 (95% CI 0.18–0.70); P = 0.003; number needed to treat (NNT) 8.5) at 36 weeks”
Find in source
03Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect on long-acting insulin requirement is an odds ratio of 0.36 (95% CI 0.18–0.70), which is statistically significant but the clinical meaningfulness is not anchored to a minimal clinically important difference or a hard outcome. The paper does not provide a threshold for what constitutes a clinically meaningful reduction in insulin requirement. Additionally, the primary outcomes showed no effect, and the secondary surrogate effect is presented without a clear anchor to clinical benefit.
“odds ratio (OR) 0.36 (95% CI 0.18–0.70); P = 0.003; number needed to treat (NNT) 8.5”
Find in source
04Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
Energy restriction to 1,200 kcal/d should be considered in evidence-based guidelines.
In conclusion, in women with gestational diabetes with a BMI ≥ 25 kg m−2, energy restriction to 1,200 kcal d−1 should be considered in evidence-based guidelines.
Discussionreviewer’s wording
05Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
A reduced-energy diet of around 1,200 kcal d−1 should be considered for evidence-based clinical practice internationally for women with gestational diabetes with a BMI ≥ 25 kg m−2.
A reduced-energy diet of around 1,200 kcal d−1 should be considered for evidence-based clinical practice internationally for women with gestational diabetes with a BMI ≥ 25 kg m−2.
Discussionreviewer’s wording

Findings by category

201ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted, rigorously reported randomized controlled trial with strong methodology, clear ethics, and transparent reporting. The main weakness is the vague data/code availability, and there are minor internal inconsistencies in reported statistics that warrant correction.

Both reviewers classified the study as interventional; no divergence. The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal housing, cell lines). The statistics verification covered only a subset of tests (8 recomputed), and the copyedit/integrity checks flagged minor CI/SD inconsistencies that do not affect the overall statistical adequacy rating.

Numerical inconsistencies

2 findings · worst high

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Recomputed 7 tests: 7 consistent, 0 inconsistent; 4 recomputed directly from the reported test statistics, 3 via agent-written checks. 1 reported summary statistic mathematically impossible for the stated N (PERCENT).

Numeric forensics— values impossible for the reported sample size

PERCENT
90.1% does not match the reported count 388/425
“388 of 425 (90.1%)”
Find in source

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .017 · recomputed p = .017
Recomputed OR 2.25 (95% CI 1.16–4.38), reported p=0.017
“OR 2.25 (95% CI 1.16, 4.38); P = 0.017”
Find in source
Taken as given: 1.16–4.38 is a two-sided 95% confidence interval for the OR of 2.25, not a range, an IQR, or a different interval level; the OR is a RATIO measure, so the interval is symmetric on the log scale; p=0.017 is the p for THIS estimate, not for another comparison in the same sentence
Method: back the two-tailed p out of the log-scale CI width and compare it against the printed p
How we recomputed it: pCI(2.25, 1.16, 4.38, 1)
CONSISTENTreported p = .027 · recomputed p = .028
Recomputed OR 0.52 (95% CI 0.29–0.93), reported p=0.027
“OR 0.52 (95% CI 0.29, 0.93); P = 0.027”
Find in source
Taken as given: 0.29–0.93 is a two-sided 95% confidence interval for the OR of 0.52, not a range, an IQR, or a different interval level; the OR is a RATIO measure, so the interval is symmetric on the log scale; p=0.027 is the p for THIS estimate, not for another comparison in the same sentence
Method: back the two-tailed p out of the log-scale CI width and compare it against the printed p
How we recomputed it: pCI(0.52, 0.29, 0.93, 1)
CONSISTENTreported p = .787 · recomputed p = .792
Recomputed OR 0.90 (95% CI 0.41–1.97), reported p=0.787
“OR 0.90 (95% CI 0.41, 1.97); P = 0.787”
Find in source
Taken as given: 0.41–1.97 is a two-sided 95% confidence interval for the OR of 0.90, not a range, an IQR, or a different interval level; the OR is a RATIO measure, so the interval is symmetric on the log scale; p=0.787 is the p for THIS estimate, not for another comparison in the same sentence
Method: back the two-tailed p out of the log-scale CI width and compare it against the printed p
How we recomputed it: pCI(0.9, 0.41, 1.97, 1)
CONSISTENTreported p = .034 · recomputed p = .037
Recomputed OR 0.48 (95% CI 0.24–0.95), reported p=0.034
“OR 0.48 (95% CI 0.24, 0.95); P = 0.034”
Find in source
Taken as given: 0.24–0.95 is a two-sided 95% confidence interval for the OR of 0.48, not a range, an IQR, or a different interval level; the OR is a RATIO measure, so the interval is symmetric on the log scale; p=0.034 is the p for THIS estimate, not for another comparison in the same sentence
Method: back the two-tailed p out of the log-scale CI width and compare it against the printed p
How we recomputed it: pCI(0.48, 0.24, 0.95, 1)
CONSISTENTreported p = .623 · recomputed p = .628Reviewer 2
Primary maternal outcome: intervention effect -0.20, 95% CI -1.01 to 0.61, P=0.623
“baseline-adjusted difference intervention versus control, β (adjusted effect size) −0.20 (95% confidence interval (CI) −1.02, 0.61); P = 0.623”
Find in source
Taken as given: The effect estimate is -0.20.; The 95% CI is -1.01 to 0.61 (using Table 2 values).; The CI is two-sided at 95%.
Method: Recomputed p-value from effect estimate and 95% CI using normal approximation.
How we recomputed it: pCI(-0.20, -1.01, 0.61, 0)
CONSISTENTreported p = .960 · recomputed p = .960Reviewer 2
Primary neonatal outcome: intervention effect 0.005, 95% CI -0.19 to 0.20, P=0.96
“offspring standardized birth weight (intervention effect 0.005 (−0.19, 0.20); P > 0.1)”
Find in source
Taken as given: The effect estimate is 0.005.; The 95% CI is -0.19 to 0.20.; The CI is two-sided at 95%.
Method: Recomputed p-value from effect estimate and 95% CI using normal approximation.
How we recomputed it: pCI(0.005, -0.19, 0.20, 0)
CONSISTENTreported p = .003 · recomputed p = .003Reviewer 2
Long-acting insulin at 36 weeks: OR 0.36, 95% CI 0.18-0.70, P=0.003
“long-acting insulin therapy (39.2% control, 27.5% intervention; odds ratio (OR) 0.36 (95% CI 0.18–0.70); P = 0.003”
Find in source
Taken as given: The OR is 0.36.; The 95% CI is 0.18 to 0.70.; The CI is two-sided at 95%.
Method: Recomputed p-value from log-OR and CI using normal approximation.
How we recomputed it: pCI(0.36, 0.18, 0.70, 1)

lowinternal contradiction
In Table 1, the SD for gestational age at diagnosis in the intervention group is 0.97, which is implausibly small compared to the control group SD of 6.54 and the overall SD of 6.40.
“Gestational age at diagnosis | 414 | 22.85 (6.40) | 204 | 22.73 (6.54) | 210 | 22.97 (0.97)”
Table 1Find in source
lowinternal contradiction
In Table 2, the row 'Also adjusted for baseline weight' shows a CI of (−0.01, 0.61), which is inconsistent with the main effect CI of (−1.01, 0.61).
“Also adjusted for baseline weight | −0.20 (−0.01, 0.61) | 0.63”
Table 2Find in source
lowinternal contradiction
The confidence interval for the primary maternal outcome is reported as −1.01 in the abstract and results text, but as −1.02 in Table 2.
intervention effect −0.20 (95% confidence interval −1.01, 0.61) ... Table 2: −0.20 (−1.01, 0.61) ... Also adjusted for baseline weight | −0.20 (−0.01, 0.61)
Table 2reviewer’s wording

Overstated conclusions

4 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

overstatedReviewer 1
Energy restriction to 1,200 kcal/d should be considered in evidence-based guidelines.
The trial did not show a significant difference in primary outcomes, and the recommendation for guidelines is based on secondary and exploratory findings, which may be overreaching.
Evidence: Primary outcomes were null; the recommendation is based on secondary outcomes (insulin reduction) and exploratory weight loss analyses.
In conclusion, in women with gestational diabetes with a BMI ≥ 25 kg m−2, energy restriction to 1,200 kcal d−1 should be considered in evidence-based guidelines.
Discussionreviewer’s wording
overstatedReviewer 2
A reduced-energy diet of around 1,200 kcal d−1 should be considered for evidence-based clinical practice internationally for women with gestational diabetes with a BMI ≥ 25 kg m−2.
The trial showed safety and reduced insulin needs, but the primary outcomes were null and the recommendation for clinical practice may be premature given the exploratory nature of some findings.
Evidence: Primary outcomes were null; secondary outcome on insulin was significant; weight loss analysis was exploratory.
A reduced-energy diet of around 1,200 kcal d−1 should be considered for evidence-based clinical practice internationally for women with gestational diabetes with a BMI ≥ 25 kg m−2.
Discussionreviewer’s wording
partialReviewers 1, 2
Weight loss in late pregnancy was associated with improved maternal glycaemia and reduced LGA infants.
The exploratory analysis shows associations, but these are from a post hoc, non-randomized comparison, so causality cannot be inferred; the paper acknowledges this.
Evidence: Exploratory analysis: weight loss associated with improved TIR, CGM glucose, and reduced LGA (OR 0.52, 95% CI 0.29–0.93).
“Weight loss in late pregnancy was associated with reduced rates of LGA infants (OR 0.52 (95% CI 0.29, 0.93); P = 0.027; Table )”
ResultsFind in source
supportedReviewers 1, 2
A reduced-energy diet was safe in pregnancy.
The paper reports no significant differences in safety outcomes (SGA, stillbirth, neonatal death, maternal death) between groups, supporting the claim.
Evidence: Safety outcomes in Table 3 show similar rates of SGA and no significant differences in serious adverse events.
“A reduced-energy diet was safe in pregnancy.”
AbstractFind in source
supportedReviewer 1
There was no difference in maternal weight change or offspring birth weight between groups.
The primary outcomes showed no statistically significant differences, with effect estimates close to zero and wide confidence intervals.
Evidence: Primary outcomes: maternal weight change β −0.20 (95% CI −1.01, 0.61), P=0.623; standardized birth weight β 0.005 (95% CI −0.19, 0.20), P=0.962.
There was no evidence of a difference in maternal weight change to 36 weeks between groups ... and offspring standardized birth weight
Abstractreviewer’s wording
supportedReviewers 1, 2
Provision of a reduced-energy diet reduced requirements for long-acting insulin therapy.
The secondary outcome showed a significant reduction in long-acting insulin use in the intervention group, with an OR of 0.36 (95% CI 0.18–0.70), P=0.003.
Evidence: Secondary outcomes in Table 3: Long-acting insulin at 36 weeks OR 0.36 (0.18, 0.70), P=0.003.
“Provision of a reduced-energy diet reduced requirements for long-acting insulin therapy (39.2% control, 27.5% intervention; odds ratio (OR) 0.36 (95% CI 0.18–0.70); P = 0.003; number needed to treat (NNT) 8.5)”
ResultsFind in source
supportedReviewer 2
There was no evidence of a difference in maternal weight change to 36 weeks between groups.
The primary outcome analysis shows a non-significant difference with a narrow CI, supporting the claim.
Evidence: Primary outcome: intervention effect −0.20 (95% CI −1.01, 0.61); P = 0.623.
“There was no evidence of a difference in maternal weight change to 36 weeks between groups (intervention effect −0.20 (95% confidence interval −1.01, 0.61); P > 0.1)”
AbstractFind in source

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

INADEQUATESurrogate endpoint
The primary efficacy claim is that a reduced-energy diet reduces the requirement for long-acting insulin in gestational diabetes. This is a surrogate outcome (medication requirement) rather than a hard clinical outcome. The paper does not demonstrate target engagement at the tested dose (e.g., no PK/PD or dose-exposure data linking the 1200 kcal diet to insulin requirement reduction) and does not cite validated evidence linking reduced insulin requirement to improved long-term clinical outcomes in gestational diabetes. The primary outcomes (maternal weight change and offspring birth weight) showed no difference, so the efficacy claim rests on this secondary surrogate.
“Provision of a reduced-energy diet reduced requirements for long-acting insulin therapy (39.2% control, 27.5% intervention; odds ratio (OR) 0.36 (95% CI 0.18–0.70); P = 0.003; number needed to treat (NNT) 8.5) at 36 weeks”
Find in source
INADEQUATEEffect size
The reported effect on long-acting insulin requirement is an odds ratio of 0.36 (95% CI 0.18–0.70), which is statistically significant but the clinical meaningfulness is not anchored to a minimal clinically important difference or a hard outcome. The paper does not provide a threshold for what constitutes a clinically meaningful reduction in insulin requirement. Additionally, the primary outcomes showed no effect, and the secondary surrogate effect is presented without a clear anchor to clinical benefit.
“odds ratio (OR) 0.36 (95% CI 0.18–0.70); P = 0.003; number needed to treat (NNT) 8.5”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on gestational diabetes, weight management in type 2 diabetes, and observational studies on gestational weight gain, and builds a logical rationale for testing energy restriction in gestational diabetes. It acknowledges gaps in existing evidence, such as the lack of intervention studies addressing gestational weight gain in this population. Limitations of prior work are implicitly addressed by the study design (e.g., using a whole-diet intervention to enable blinding).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with adequate citation of prior work and a logical rationale for the study.

Evidence

“Several recent retrospective cohort studies have identified that weight gain below the guidelines, or even weight loss, may improve pregnancy outcomes in women with prepregnancy obesity or gestational diabetes”

Main, paragraphs 1-3Find in source

“Reduced-energy diets promote weight loss and improve long-term outcomes in type 2 diabetes but are untested in gestational diabetes.”

Main, paragraph 1Find in source

“Multiple small studies have assessed different diets in gestational diabetes, usually through the provision of tailored dietary advice, but have had low statistical power to examine pregnancy outcomes.”

Discussion ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on gestational diabetes, weight management, and dietary interventions, and logically links this to the study's objectives.

Evidence

paraphrase[Main, first paragraph]

“Gestational diabetes affects 6–15% of pregnancies internationally and is associated with suboptimal maternal and offspring outcomes.”

paraphrase[Main, first paragraph]

“In non-pregnant people with type 2 diabetes, weight loss improves glycaemia and reduces medication requirements, leading to remission of clinical diabetes.”

“Despite the mounting evidence favoring reduced gestational weight gain in women with gestational diabetes, there are very few intervention studies that have successfully addressed gestational weight gain in this population.”

Main, first paragraphFind in source

Randomization method is described (permuted blocks of size 6, stratified by center, using 'blockrand' in R). Blinding is double-blind (participants and study team). Power analysis is reported, including a revised sample size based on interim analysis. Inclusion/exclusion criteria are detailed. Outlier handling is addressed through sensitivity analyses and multiple imputation. Controls are appropriate (standard-energy diet). Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, sample size calculation, and pre-specified inclusion/exclusion criteria.

Evidence

“The randomization was done in permuted blocks of size 6, in a 1:1 ratio and stratified by center.”

MethodsFind in source

“randomized, controlled, double-blind trial”

AbstractFind in source

“The original sample size was n = 500, which provided >90% power to identify a 0.33 s.d. (1 kg) difference in maternal weight change between groups”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, sample size calculation, and pre-specified inclusion/exclusion criteria.

Evidence

“The randomization was done in permuted blocks of size 6, in a 1:1 ratio and stratified by center.”

MethodsFind in source

“The randomization was performed in a 1:1 ratio, stratified by center and blinded to the participants and study team.”

AbstractFind in source

paraphrase[Methods, Sample size calculation]

“The original sample size was n = 500, which provided >90% power to identify a 0.33 s.d. (1 kg) difference in maternal weight change between groups.”

Sex is reported (all participants assigned female sex at birth). Age, BMI, and health status are reported in baseline characteristics. Demographics include ethnicity, education, and deprivation index. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, BMI, and demographics.

Evidence

“This study included pregnant individuals who were assigned female sex at birth.”

MethodsFind in source

“Maternal age (years) | 425 | 33.03 (5.04)”

Table 1Find in source

paraphrase[Table 1]

“Self-reported ethnicity | White | 332 (78.12)”

PASSReviewer 2· 90% conf

The study reports key biological variables including sex (all female), age, BMI, and health status, with demographics detailed.

Evidence

“Maternal age (years) | 425 | 33.03 (5.04) | 211 | 32.80 (5.11) | 214 | 33.26 (4.97)”

Table 1Find in source

paraphrase[Table 1]

“Self-reported ethnicity | 425 | 211 | 214 | White | 332 (78.12) | 163 (77.25) | 169 (78.97)”

The trial was approved by a named ethics committee (National Research Ethics Committee, UK) with reference numbers, and informed consent was obtained from all participants. Regulatory compliance with the Declaration of Helsinki is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

“The protocol was approved by the National Research Ethics Committee, United Kingdom (reference 18/WM/0191)”

MethodsFind in source

“Written informed consent was obtained from all participants.”

MethodsFind in source

“The trial was conducted in accordance with the Declaration of Helsinki”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial has clear ethics approval from a named committee, informed consent, and regulatory compliance.

Evidence

paraphrase[Methods, Trial oversight]

“The trial was conducted in accordance with the Declaration of Helsinki and the protocol was approved by the National Research Ethics Committee, United Kingdom (reference 18/WM/0191) and the NHS Health Research Authority (IRAS 242924; ISRCTN 65152174).”

“Written informed consent was obtained from all participants.”

MethodsFind in source

The diet boxes are described with energy content and macronutrient composition, and the industrial partner is named. Statistical software (STATA, R) and database (Castor) are identified. No antibodies, cell lines, or organisms are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (diet boxes) is adequately described, and software tools are identified.

Evidence

paraphrase[Methods, Intervention and control]

“The diet boxes contain 2,000 kcal d−1 (control) or 1,200 kcal d−1 (reduced-energy intervention) comprising 40% carbohydrate, 25% protein and 35% fat.”

“Analysis was performed in STATA (v.17.0; StataCorp).”

Statistical analysisFind in source

“Randomization was implemented using the library ‘blockrand’ in the statistical package R.”

MethodsFind in source

PASSReviewer 2· 85% conf

The investigational product (diet boxes) is adequately described, and software tools are identified.

Evidence

paraphrase[Methods, Intervention and control]

“The diet boxes contain 2,000 kcal d−1 (control) or 1,200 kcal d−1 (reduced-energy intervention) comprising 40% carbohydrate, 25% protein and 35% fat.”

“Analysis was performed in STATA (v.17.0; StataCorp).”

Statistical analysisFind in source

Statistical tests are named (linear and logistic regression). Assumptions are handled by design (pre-specified models). Exact p-values are reported for primary and secondary outcomes. Effect sizes with 95% CIs are reported throughout. Software is identified. Data presentation includes per-group n and dispersion measures. Mathematical plausibility checks were not possible for most continuous outcomes due to large N, but no obvious errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-reported, with exact p-values and effect sizes with confidence intervals.

Evidence

“regression coefficients for linear or logistic regression, adjusted for baseline values for continuous outcomes, were used to assess intervention effects”

Statistical analysisFind in source

paraphrase[Results, Primary outcomes]

“P = 0.623”

“β (adjusted effect size) −0.20 (95% confidence interval (CI) −1.02, 0.61)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are well-described, with named tests, effect sizes with confidence intervals, and appropriate data presentation.

Evidence

“With stratification by study center, regression coefficients for linear or logistic regression, adjusted for baseline values for continuous outcomes, were used to assess intervention effects for all continuous or categorical outcomes respectively.”

Statistical analysisFind in source

“baseline-adjusted difference intervention versus control, β (adjusted effect size) −0.20 (95% confidence interval (CI) −1.02, 0.61); P = 0.623”

ResultsFind in source

The data availability statement says anonymized individual participant data is available upon request from the corresponding author, subject to approval, but does not specify a platform or detailed conditions beyond 'subject to approval from trial steering groups and data sharing and processing agreements.' The timeframe is stated (within 1 month). Code is available on request but not in a public repository. Repository deposit and accession numbers are not applicable for identifiable patient data.

Sub-criteria

code sharingINADEQUATE

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 90% conf

Data availability statement is present but vague, and code is only available on request.

Evidence

“Anonymized individual participant data is available upon request from the corresponding author (cm881@leicester.ac.uk), subject to approval from trial steering groups and data sharing and processing agreements.”

Data availabilityFind in source

“Stata code is available for this trial upon request from the corresponding author.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

Data availability statement is present but vague, and code is only available upon request without a repository.

Evidence

Data availabilityFind in source

“Stata code is available for this trial upon request from the corresponding author.”

Data availabilityFind in source

The trial is registered (ISRCTN65152174). Methods are detailed enough for replication. A reporting guideline is not explicitly mentioned, but the paper follows CONSORT-like structure. All pre-specified outcomes are reported, including null results. Limitations are discussed extensively. Conclusions are proportional to the evidence, with careful language about associations. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Reporting is transparent with trial registration, detailed methods, limitations, and proportional conclusions.

Evidence

“ISRCTN registration no. 65152174”

AbstractFind in source

“This study has several limitations.”

Discussion ¶8Find in source

paraphrase[Acknowledgements]

“The DiGest clinical research trial was funded by Diabetes UK through a Harry Keen Intermediate Clinical Fellowship to C.L.M. (17/0005712; ISRCTN number 65152174)”

PASSReviewer 2· 90% conf

The manuscript is transparent with detailed methods, trial registration, discussion of limitations, and proportional conclusions.

Evidence

paraphrase[Abstract]

“ISRCTN registration no. 65152174 (https://www.isrctn.com/ISRCTN65152174).”

“This study has several limitations. Our study population was more ethnically diverse than the UK population, but still had relatively small numbers of women from non-white backgrounds.”

DiscussionFind in source

Registered (1 ID: ISRCTN). No reporting guideline cited.

ISRCTN

ISRCTN65152174

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 36 references by DOI: 2 verified — 34 no DOI (shown, not verified).

NO DOI
Maternal obesity and risk of gestational diabetes mellitus
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Gestational diabetes mellitus
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Gestational diabetes mellitus and diet: a systematic review and meta-analysis of randomized controlled trials examining the impact of modified dietary interventions on maternal glucose control and neonatal birth weight
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of weight loss by low-calorie diet on cardiovascular health in type 2 diabetes: an interventional cohort study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Weight Gain During Pregnancy: Reexamining the Guidelines
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Inadequate weight gain according to the Institute of Medicine 2009 Guidelines in women with gestational diabetes: frequency, clinical predictors, and the association with pregnancy outcomes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Low gestational weight gain (+2.0 to 4.9 kg) for singleton-term gestations associated with favorable perinatal outcomes for all prepregnancy obesity classes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Women with gestational diabetes mellitus randomized to a higher-complex carbohydrate/low-fat diet manifest lower adipose tissue insulin resistance, inflammation, glucose, and free fatty acids: a pilot study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Low-carbohydrate diet for the treatment of gestational diabetes mellitus: a randomized controlled trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Dietary intervention in patients with gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials on maternal and newborn outcomes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Randomization to a provided higher-complex-carbohydrate versus conventional diet in gestational diabetes mellitus results in similar newborn adiposity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effects of a modestly lower carbohydrate diet in gestational diabetes: a randomized controlled trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
TIMER: a clinical study of energy restriction in women with gestational diabetes mellitus
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A randomised controlled trial of dietary energy restriction in the management of obese women with gestational diabetes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Metabolic effects of 1200-kcal diet in obese pregnant women with gestational diabetes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Liver triacylglycerol content and gestational diabetes: effects of moderate energy restriction
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A high birth weight is associated with increased risk of type 2 diabetes and obesity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Birth weight and subsequent risk of obesity: a systematic review and meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Antenatal determinants of childhood obesity in high-risk offspring: protocol for the DiGest follow-up study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Weight change and cardiometabolic outcomes in postpartum women with history of gestational diabetes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The carbohydrate threshold in pregnancy and gestational diabetes: how low can we go?
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Dietary intervention in pregnant women with gestational diabetes; protocol for the DiGest randomised controlled trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Guidance for Maternal Medicine Services in the Coronavirus (COVID-19) Pandemic
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Customised antenatal growth charts
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Adjusting for partially missing baseline measurements in randomized trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

1 data/code link checked; 1 live.

datahttps://www.isrctn.com/ISRCTN65152174LIVEHTTP 200
Resolved page looks like data.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

MINORconsistencyTable 1, Gestational age at diagnosis
“22.97 (0.97)”
→ Check if the standard deviation is plausible; likely a typo for 6.97 or similar.
The SD of 0.97 for gestational age at diagnosis seems implausibly small compared to other values.
MINORclarityResults, Primary outcomes
“β −0.20 (95% CI −1.02, 0.61)”
→ Ensure the CI is consistently reported as −1.01 in the text and −1.02 in the table.
There is a minor discrepancy in the lower bound of the CI between text and table.
MINORconsistencyTable 2, Maternal primary outcome
“−0.20 (−0.01, 0.61)”
→ Check the CI for the adjusted effect; the lower bound appears to be a typo.
The CI lower bound is listed as −0.01, which is inconsistent with the text's −1.01.
MINORconsistencyTable 1, Gestational age at diagnosis
“22.97 (0.97)”
→ Check if the SD is plausible; likely a typo for 22.97 (6.40) or similar.
The SD of 0.97 for gestational age at diagnosis seems too small compared to other groups.
MINORclarityResults, Primary outcomes
“β −0.20 (95% CI −1.02, 0.61)”
→ Ensure consistency with Table 2 where CI is −1.01, 0.61.
Minor discrepancy in CI bounds between text and table.
MINORtypoTable 4, Weight change
“2.10 (1.10–3.60)”
→ Check if this is a median (IQR) and should be in bold.
Formatting inconsistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and generally trustworthy, but an informed reader should weigh the minor internal inconsistencies in reported confidence intervals and a plausibility concern in Table 1, as well as the limited data/code availability. These issues do not invalidate the main conclusions but warrant a correction or erratum for the CI discrepancies and a clearer data-sharing statement.

1.
HIGHstatistics
In Table 2 and the Results text, reconcile the confidence interval for the primary maternal outcome: the lower bound is reported as −1.02 in the text and −1.01 in the table; ensure they match.
An internal inconsistency in the primary outcome CI undermines the paper's credibility and could be flagged by readers or reviewers.
2.
HIGHstatistics
In Table 2, correct the CI for the row 'Also adjusted for baseline weight' from (−0.01, 0.61) to match the main effect CI (likely −1.01, 0.61).
The current CI lower bound of −0.01 is implausible and inconsistent with the main analysis, suggesting a typographical error.
3.
HIGHstatistics
In Table 1, verify the standard deviation for gestational age at diagnosis in the intervention group (reported as 0.97); it is implausibly small compared to the control group (6.54) and overall (6.40).
An SD of 0.97 for gestational age at diagnosis is likely a typo and could indicate a data error; correct it to the plausible value.
4.
HIGHreporting
In the Discussion, temper the claims that a reduced-energy diet of ~1,200 kcal/d 'should be considered in evidence-based guidelines' and 'should be considered for evidence-based clinical practice internationally' to reflect that the primary outcomes were null and these recommendations are based on secondary/exploratory findings.
The claim audit flagged these statements as overstated; over-claiming from null primary outcomes is a common reviewer objection and could mislead readers.
5.
MEDIUMdata code
In the Data availability section, specify a concrete data-sharing platform (e.g., a managed-access repository like Vivli or a named data access committee) and detail the conditions for access, including the review process and timeline.
The current statement is vague ('subject to approval') and would be strengthened by a concrete route, improving transparency and reproducibility.
6.
MEDIUMdata code
In the Code availability section, deposit the Stata code in a public repository (e.g., Zenodo or GitHub) with a DOI.
Code available only on request limits independent verification; a public deposit with a DOI is the expected standard for reproducibility.
7.
MEDIUMreporting
In the Methods or Reporting Summary, explicitly state adherence to the CONSORT reporting guideline and consider including a completed CONSORT checklist as supplementary material.
One reviewer noted the reporting guideline was not explicitly mentioned; explicit adherence strengthens transparency and is expected for RCTs.
8.
LOWcopyedit
In Table 4, check whether the weight change value '2.10 (1.10–3.60)' is a median (IQR) and format it consistently (e.g., bold or with a footnote).
Formatting inconsistency in the table could confuse readers.

Full text (68,464 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Reduced-energy diet in women with gestational diabetes: the dietary intervention in gestational diabetes DiGest randomized clinical trial.

Kusinski LC, Jones D, Atta N, Turner E, Smith S, Oude Griep LM, Rennie K, De Lucia Rolfe E, Sharp SJ, Farewell V, Murphy HR, Taylor R, Meek CL

DOI

10.1038/s41591-024-03356-1

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-20